Teva's TAPI Unit Taps Industry Veteran Rogasik as CEO to Drive Growth

  • Serge Rogasik appointed CEO of TAPI (Technology & API Services), a Teva Pharmaceutical Industries Ltd unit, effective September 30, 2026.
  • Rogasik brings 25 years of experience in transforming specialty ingredients and life sciences businesses, including leading Kensing through multiple acquisitions.
  • TAPI operates 13 manufacturing sites and six R&D facilities globally, supplying 350+ active pharmaceutical ingredients to customers worldwide.
  • Rogasik will focus on leveraging TAPI's broad API portfolio and global operations network to enhance supply chain resilience and geographic diversification.

TAPI's appointment of Rogasik underscores Teva's focus on strengthening its API and CDMO capabilities amid industry-wide shifts towards supply chain resilience. Rogasik's background in carve-outs and operational improvements positions him to drive TAPI's growth in a highly regulated market. The move comes as pharmaceutical companies increasingly prioritize geographic diversification to mitigate risks.

Execution Risk
How Rogasik's track record in transforming carve-outs will translate to TAPI's integrated API and CDMO businesses.
Market Positioning
Whether TAPI can sustain its leadership in supply chain resilience amid increasing competition in the API sector.
Strategic Acquisitions
The pace at which Rogasik pursues M&A to expand TAPI's global footprint and technology platform.